Page 163 - Genentech News Today

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application

Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further

Pending FDA approval, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration and diabetic macular edema.

The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In

Award Will Support 1st Annual Spinal Cord Injury Investor Symposium To Be Held June 29, 2023 ... | May 9, 2023

The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery...

/PRNewswire/ -- DelveInsights Acute Ischemic Stroke Market Insights report includes a comprehensive understanding of current treatment practices, acute...

The dynamics of the acute ischemic stroke (AIS) market are anticipated to change during the forecast period (2023-2032) owing to the improved knowledge of stroke pathophysiology, awareness of

These 2 randomized clinical trials compare the efficacy and safety of 2 doses of the autotaxin inhibitor ziritaxestat vs placebo in patients with idiopathic pul

Operator: Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.